Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Semax Amidate Benefits: Research Comparison

The table below compares Semax amidate against standard Semax and related nootropic peptides across key research parameters. Understanding these differences helps researchers select the appropriate compound for specific study designs and outcome measures. Sema

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • The table below compares Semax amidate against standard Semax and related nootropic peptides across key research parameters. Understanding these differences helps researchers select the appropriate compound for specific study designs and outcome measures.
  • Semax Amidate
  • 4–6 hours
  • BDNF upregulation, melanocortin receptor modulation, monoamine metabolism
  • 50–500 mcg/kg intranasal
  • Intranasal, subcutaneous
  • Gold standard for extended-duration cognitive studies. Structural stability allows lower dosing frequency and consistent plasma levels across observation windows
  • Standard Semax
  • 10–15 minutes
  • Identical mechanism, lower stability
  • 200–1000 mcg/kg intranasal (higher to compensate)
  • Requires higher doses and more frequent administration due to rapid enzymatic degradation. Useful for acute-phase studies but impractical for multi-week protocols
  • Selank Amidate
  • 3–5 hours
  • Anxiolytic through enkephalin modulation, not melanocortin
  • 100–400 mcg/kg intranasal
  • Intranasal
  • Complementary rather than comparable. Targets anxiety and stress response rather than cognitive performance, though some overlap in HPA axis effects
  • Dihexa
  • 2–4 hours (oral)
  • HGF/c-Met pathway, synaptic density increase
  • 1–5 mg/kg oral
  • Oral (unique among cognitive peptides)
  • Structurally distinct. Small molecule rather than peptide, crosses BBB via different mechanism, used for neurogenesis rather than neurotransmitter modulation
  • P21
  • 30–60 minutes
  • CREB activation, derived from CNTF
  • 1–10 mg/kg intranasal
  • Potent but short half-life limits application to acute dosing studies. Best for examining immediate post-learning consolidation windows